Summary
Boston Scientific Corporation's (BSX) 2011 Form 10-K highlights a year of strategic repositioning and operational adjustments. The company reported net sales of $7.62 billion, a slight decrease from the prior year, impacted by the divestiture of its Neurovascular business. Despite the sales decline, adjusted net income remained robust, reflecting successful cost-containment measures and restructuring initiatives aimed at improving operational efficiency and profitability. The company continued to invest in research and development, focusing on innovation across its key business segments, including Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, and Peripheral Interventions. Key financial and operational themes for 2011 include managing pricing pressures in core markets like coronary stents and CRM, investing in emerging markets, and navigating a complex regulatory and reimbursement environment. The company made significant strides in debt reduction, improving its credit ratings, and repurchased a substantial amount of its common stock. Despite facing challenges such as competition and evolving healthcare policies, Boston Scientific emphasized its commitment to innovation and delivering value to patients and shareholders through its diversified portfolio of less-invasive medical devices.
Financial Highlights
52 data points| Revenue | $7.62B |
| Cost of Revenue | $2.66B |
| Gross Profit | $4.96B |
| SG&A Expenses | $2.49B |
| Operating Expenses | $4.06B |
| Operating Income | $904.00M |
| Interest Expense | $281.00M |
| Net Income | $441.00M |
| EPS (Basic) | $0.29 |
| EPS (Diluted) | $0.29 |
| Shares Outstanding (Basic) | 1.51B |
| Shares Outstanding (Diluted) | 1.52B |
Key Highlights
- 1Net sales for 2011 were $7.62 billion, a 2% decrease from $7.81 billion in 2010, primarily due to the divestiture of the Neurovascular business and declines in Interventional Cardiology and CRM segments, partially offset by favorable foreign currency fluctuations.
- 2Reported net income was $441 million ($0.29 per share) in 2011, compared to a net loss of $1.065 billion (-$0.70 per share) in 2010. Adjusted net income (excluding special items) was $1.018 billion ($0.67 per share) in 2011, compared to $1.051 billion ($0.69 per share) in 2010.
- 3The company recorded a significant goodwill impairment charge of $697 million in Q1 2011 related to its U.S. Cardiac Rhythm Management (CRM) business, reflecting market pressures and revised revenue projections.
- 4Boston Scientific completed the sale of its Neurovascular business to Stryker Corporation in January 2011 for $1.5 billion in cash, contributing to a substantial debt reduction.
- 5The company continued its restructuring efforts, including the 2011 Restructuring plan, 2010 Restructuring plan, and Plant Network Optimization program, aimed at improving operational effectiveness, efficiency, and competitiveness.
- 6Significant investments were made in strategic growth areas, including acquisitions in structural heart therapy (Sadra Medical, Inc.) and atrial fibrillation (Atritech, Inc.), and continued expansion in emerging markets like China, Brazil, and India.
- 7Debt levels were reduced by $1.177 billion in 2011, and the company's credit ratings were maintained at investment grade by major agencies, reflecting improved financial fundamentals.